A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies
NCT00719836
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
76
Enrollment
INDUSTRY
Sponsor class
Conditions
Acute Myelogenous Leukemia
Chronic Myelogenous Leukemia
Chronic Myelomonocytic Leukemia
Myelodysplastic Syndromes
Myelofibrosis
Interventions
DRUG:
SB1518
Sponsor
S*BIO